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The emergence of skin-containing vascularized composite allografts (VCAs) has provided impetus to understand factors affecting rejection and tolerance of skin. VCA tolerance can be established in miniature swine across haploidentical MHC barriers using mixed chimerism. Because the deceased donor pool for VCAs does not permit MHC antigen matching, clinical VCAs are transplanted across varying MHC disparities. We investigated whether sharing of MHC class I or II antigens between donors and recipients influences VCA skin tolerance. Miniature swine were conditioned nonmyeloablatively and received hematopoietic stem cell transplants and VCAs across MHC class I (n = 3) or class II (n = 3) barriers. In vitro immune responsiveness was assessed, and VCA skin-resident leukocytes were characterized by flow cytometry. Stable mixed chimerism was established in all animals. MHC class II-mismatched chimeras were tolerant of VCAs. MHC class I-mismatched animals, however, rejected VCA skin, characterized by infiltration of recipient-type CD8 + lymphocytes. Systemic donor-specific nonresponsiveness was maintained, including after VCA rejection. This study shows that MHC antigen matching influences VCA skin rejection and suggests that local regulation of immune tolerance is critical in long-term acceptance of all VCA components. These results help elucidate novel mechanisms underlying skin tolerance and identify clinically relevant VCA tolerance strategies.
Introduction
Skin transplants have been used extensively for >70 years in animal studies of transplant immunology, and the longterm acceptance of a skin graft represents one of the most stringent tests of tolerance (1) . The tendency of transplanted skin to reject more readily than other organs and tissues has been well appreciated, but the mechanisms underlying this observation have remained enigmatic (2) . Proposed explanations have included the presence of skinspecific alloantigens and the intrinsic immune function of the skin, which contains large numbers of resident memory T cells and specialized antigen-presenting cells such as Langerhans cells (3, 4) .
The emergence of vascularized composite allograft (VCA) transplantation for reconstructive purposes over the past 17 years has provided new clinical impetus to understand factors that govern skin rejection (5) (6) (7) . These transplants involve primarily vascularized units composed of multiple tissue types, including skin, fascia, muscle, nerve, and bone and have been used to restore form and function in persons with extensive disfigurements. Hand and face transplants, in particular, have now been used in the reconstruction of upper limb amputees as well as those affected by malignancies, burns, radiation injuries, disfiguring immunological conditions, severe infections, and genetic abnormalities (8) (9) (10) (11) . Follow-up reports have consistently demonstrated superior functional and quality-of-life recovery in VCA recipients in comparison to more conventional reconstructive methods (12) (13) (14) (15) . Despite this, reconstructive transplantation remains controversial: In contrast to life-saving solid organ transplants, the persistent ethical question remains whether the life-enhancing benefits of VCAs are justified by the risks of lifelong immunosuppression such as malignancies, organ dysfunction, and infections, all of which have been reported in VCA recipients (12, 13, 15) . Protocols permitting VCA tolerance, in which there is the specific absence of a destructive immune response to the allograft in the absence of immunosuppression, would fundamentally shift the risk-benefit ratio and allow widespread application of this highly promising reconstructive modality.
Our laboratory recently demonstrated long-term tolerance of skin-containing VCAs in a preclinical large animal model (16) . Miniature swine recipients underwent a nonmyeloablative conditioning regimen for induction of mixed chimerism across major histocompatibility barriers, and long-term, immunosuppression-free VCA survival was demonstrated, with no clinical or histologic evidence of skin rejection at any time point (16) . In this experiment, however, VCA tolerance was established across a haploidentical MHC barrier at which there was partial sharing of antigens at MHC classes I and II between donors and recipients.
Given that the existing deceased donor pool for VCA transplantation does not permit MHC antigen matching, clinical VCA transplants to date have been performed across varying disparities including full MHC mismatches (17) . Consequently, determining the role of MHC matching in VCA skin tolerance will be critical in establishing a clinically feasible tolerance protocol. In this study, we examined whether matching of MHC class I or II antigens between donors and recipients influences tolerance of VCA skin in a preclinical large animal model. The results of this study provided novel insights into factors that mediate the tolerance of skin, with potential implications for clinical VCA tolerance protocols.
Materials and Methods

Animals
This study utilized the Massachusetts General Hospital (MGH) miniature swine model (18 Figure 1A ). Pig allelic antigen (PAA), a nonhistocompatibility antigen, was mismatched between donor and recipient animals to allow monitoring of origin of hematopoietic cell lineages following hematopoietic stem cell transplantation (HSCT) (19) .
All animal care and procedures were approved by the MGH institutional animal care and use committee and conducted in compliance with the Guide for the Care and Use of Laboratory Animals prepared by the 
Nonmyeloablative conditioning to establish stable mixed chimerism
Recipient animals underwent nonmyeloablative conditioning using an established regimen to induce stable mixed chimerism (20) . Animals underwent transient, partial T cell depletion with a CD3 immunotoxin (recombinant CD3 immunotoxin pCD3-DT390 50 ug/kg intravenously twice daily from day À4 to À1) and 100 cGy total body irradiation on day À2 (21). Cyclosporine A was given intravenously starting on day À2 and continued to day 30 with a trough level target of 400-800 ng/mL. After day 30, the dose of cyclosporine A was tapered to discontinuation by day 45 ( Figure 1B ).
Hematopoietic stem cells were taken from donor animals that had received seven doses of porcine IL-3 and porcine stem cell factor, calculated according to body weight. Cytokine-mobilized peripheral blood stem cells were collected by leukapheresis of the donor animal and transfused to the recipient at a target dose of 15 9 10 9 cells/kg recipient weight over days 0, 1, and 2.
VCA transplantation and rejection monitoring
VCA transplants, consisting of primarily vascularized skin flaps, were performed on day 3. Donor miniature swine animals were anesthetized, placed supine on the operating table, and prepared for surgery. A paddle of skin measuring %100 cm 2 was elevated on the medial aspect of the leg, along with underlying subcutaneous tissue and fascia. The saphenous vessels were identified and preserved as the vascular pedicle. The saphenous vessels were carefully dissected to their junction with the femoral vessels, and 2 cm of the femoral vessels were harvested for the vascular anastomosis (22) . On division of the vascular pedicle, the femoral artery was flushed with 100 U/mL heparinized saline.
The recipient animals were prepared using a 5-cm paramedian incision in the neck to expose the right common carotid artery and right internal jugular vein. Vascular anastomoses between the common carotid artery/ jugular vein and the femoral vessels were performed under microscopic magnification.
Postoperatively, VCAs were monitored daily for clinical signs of rejection, defined by redness, swelling, and skin crusting. Tolerance was defined as rejection-free VCA survival for 100 days off immunosuppression. VCA and host skin biopsies were performed at weeks 2 and 4 and after days 50, 150, 200, and 250. VCA biopsies were also taken during any acute rejection crises. Biopsied tissue containing epidermis, dermis, and fascia was fixed in formalin, stained with hematoxylin and eosin, and analyzed under light microscopy. Scoring of rejection was performed without knowledge of the clinical status of the VCA based on the Banff criteria (23) . Immunohistochemistry was performed on formalin-fixed, paraffinembedded specimens using antibodies for CD3 (rabbit anti-human CD3 [Dako, Carpinteria, CA] and FoxP3 (rat anti-FoxP3 [eBioscience, San Diego, CA]).
Chimerism monitoring
Chimerism (percentage of donor leukocytes) was assessed in the peripheral blood by flow cytometry twice weekly during the first week and once weekly thereafter. Thymic biopsy specimens taken on day 150 were assessed for chimerism following preparation of single-cell suspensions. Cells were extracted from thymic biopsies by mechanical dissociation, dilution with Hank's balanced salt solution (HBSS), and filtration through a 40-lm filter.
The following swine-specific antibodies were used to assess chimerism: CD3 (898H2-6-15), CD4 (74-12-4), CD8a (76-2-11), CD172 (74-22-15), CD16 (G7), CD25 (231.3B2), and PAA (1038H-10-9; IgMK). Samples were acquired on a FACSCalibur (Becton Dickinson, Franklin Lakes, NJ), and data were analyzed with FlowJo (FlowJo LLC, Ashland, OR).
Preparation of peripheral blood mononuclear cells
Freshly heparinized whole blood was diluted approximately 1:2 with HBSS (Gibco BRL; Thermo Fisher Scientific, Waltham, MA), and the mononuclear cells were obtained by means of gradient centrifugation with Histopaque (Sigma-Aldrich, St. Louis, MO). The mononuclear cells were washed once with HBSS, and contaminating red cells were lysed with ammonium chloride potassium lysing buffer (Bio Whittaker, Inc, Walkersville, MD). Cells were then washed with HBSS and resuspended in tissue culture medium. All peripheral blood mononuclear cell (PBMC) suspensions were kept at 4°C until used in cellular assays.
Mixed lymphocyte reaction and cell-mediated lympholysis assays
Mixed lymphocyte reaction (MLR) assays were performed to assess in vitro responsiveness to donor antigens across MHC class II barriers (24) . Responder PBMCs from recipient animals were labeled with cell proliferation dye eFluor670 (eBioscience). Under vortex agitation, an eFluor670 solution was added to responder PBMCs and incubated at 37°C for 10 min. The responder cells were subsequently washed, counted, and resuspended at 4 9 10 6 cells/mL. Stimulator PBMCs from donor or donor MHC-matched animals (4 9 10 6 cells/mL) were irradiated at 2500 cGy. Labeled responder and stimulator cells were plated together in 96-well plates (Costar Corning, Lowell, MA) and incubated for 5 days at 37°C in 5% carbon dioxide and 100% humidity. Following this, cell proliferation of responder cells was analyzed with flow cytometry using FACSCalibur (Becton Dickinson).
Cell-mediated lympholysis (CML) assays were performed to assess in vitro responsiveness to donor antigens across MHC class I barriers (24) . PBMC cultures containing 4 9 10 6 cells/mL responder and 4 9 10 6 cells/mL stimulator (irradiated with 2500 cGy) were incubated for 6 days at 37°C in 7.5% carbon dioxide and 100% humidity. Bulk cultures were harvested, and effectors were tested for cytotoxic activity on chromium Cr 51 ( The role of CD25 + cells in maintaining nonresponsiveness in vitro was examined by performing CD25 + cell-depleted MLR and CML assays using magnetic activated cell sorting. PBMCs were stained using biotinylated anti-swine a-CD25 Bio (231.3B2), followed by streptavidin phycoerythrin exposure, and depleted using a-phycoerythrin beads and LD columns (Miltenyi Biotech, Cambridge, MA) prior to plating in MLR or CML assays.
Assessment of alloantibody
The presence of antidonor immunoglobulin (IgM and IgG) in the serum of experimental swine was examined by indirect flow cytometry using a The presence of cytotoxic antibodies related to cell-surface antigens in the serum of experimental swine was determined using an antibodycomplement reaction followed by a dye-exclusion assay and flow cytometry to determine the amount of target cell lysis. Sera of the experimental animals were serially diluted with cytotoxicity media consisting of 100 mL of Media 99 (Mediatech, Manassas, VA) and 2 mL of decomplemented fetal bovine serum in a 96-well plate format. Next, 1.25 9 10 5 target cells were added to each well and incubated for 15 min at 37°C. Prior to acquisition, 7-aminoactinomycin D, a fluorescent dye that intercalates into double-stranded nucleic acids and is excluded by viable cells, was added to each sample to detect lysed cells.
Isolation and characterization of skin resident leukocytes
Punch biopsies taken from the VCA and host skin were placed overnight in digestion buffer (500 mL RPMI medium with L-glutamine, 30 mL of fetal bovine serum, 5.4 mL of 1M HEPES buffer, 5 mL of DNASE I, 5 mL of penicillin/streptomycin and 5 mL primacin) and 10% dispase.
The following day, the epidermis was separated from the dermis using a pair of fine forceps.
Epidermis samples were placed in HBSS with trypsin. Samples were agitated on a heat shaker for 30 min. Digestion buffer was subsequently added to dilute the trypsin. Epidermis samples were then centrifuged and resuspended in fluorescence-activated cell sorting (FACS) media. The dermis was added to digestion buffer with collagenase and placed in an incubator at 37°C. The dermis samples were filtered, centrifuged, and resuspended in FACS media. The cells from the epidermis and dermis were stained with the following swine-specific antibodies: CD3 (898H2-6-15), CD4 (74-12-4), CD8a (76-2-11), CD16 (G7), and PAA (1038H-10-9) and analyzed with flow cytometry.
Results
Stable multilineage mixed chimerism was established across MHC class I and II barriers using nonmyeloablative conditioning Recipient animals underwent the nonmyeloablative conditioning regimen and received cytokine-mobilized peripheral blood stem cells at a target dose of 15 9 10 9 cells/ kg across MHC class II or I barriers ( Figures 1A and B) . In animals that received HSCT and VCAs across a full MHC class II barrier (n = 3), mixed chimerism across multiple lineages was established and persisted following cessation of immunosuppression (Figure 2A) . One MHC class II-mismatched chimeric animal (21508) developed acute cutaneous graft-versus-host disease (GvHD) during tapering of cyclosporine A (day 38), characterized by a maculopapular rash in the axillae and groin. Although this resolved following treatment with steroids, this animal subsequently developed clinical features consistent with chronic GvHD including diarrhea, weight loss, and skin involvement and was euthanized on day 190. At the time of euthanasia, the animal had demonstrated rejectionfree VCA survival off all immunosuppression for >100 days (Table 1) Figure 2B) . None of the MHC class I-mismatched chimeric animals developed GvHD.
Persistent thymic chimerism was seen after day 150 across MHC class II and I barriers ( Figure 3) . When comparing trends in peripheral blood chimerism, stable multilineage macrochimerism was seen across MHC class II and I barriers. Importantly, persistent chimerism was seen in the myeloid lineages. In the MHC class Imismatched setting, higher levels of NK cell and CD8 + lymphocyte chimerism were generally seen. MHC class I-mismatched chimera 22267 demonstrated lower levels of myeloid chimerism than other animals in this study. Polymerase chain reaction analysis of colonyforming units from bone marrow biopsy specimens taken on day 150 in this animal confirmed bone marrow engraftment of donor hematopoietic cells (data not shown).
MHC class II-mismatched chimeras are tolerant of VCAs, but MHC class I-mismatched chimeras reject VCA skin Following cessation of immunosuppression, MHC class II-mismatched chimeric animals demonstrated rejectionfree acceptance of all components of VCAs, including skin, for the duration of the study (190 to >530 days) ( Table 1 and Figure 4A ). Histologic analysis of protocol skin biopsies demonstrated no significant features of skin rejection at any time point.
In contrast, all MHC class I-mismatched chimeric animals demonstrated rejection episodes of their VCAs (Table 1 and Figure 4B ). Specifically, after immunosuppression was tapered, animal 21656 experienced three acute rejection episodes, on days 48, 71, and 98, characterized by redness and crusting of the VCA. The first two of these crises spontaneously resolved without treatment. Histologic analysis of skin biopsies taken during these acute rejection episodes revealed grade 3-4 rejection of the VCA epidermis, with cellular infiltrate seen at the dermoepidermal junction ( Figure 4B ). The final VCA acute rejection episode in animal 21656 resulted in sloughing of the epidermis on day 99, followed by reepithelialization from the surrounding host skin. Underlying VCA dermis and fascia remained intact.
Animal 21657 experienced one acute rejection crisis of the VCA on day 42, coinciding with the taper of immunosuppression. Biopsy at this time demonstrated grade 3-4 rejection of the VCA epidermis. This acute rejection episode spontaneously resolved without further acute rejection crises; however, the VCA subsequently appeared discolored and thickened, and serial biopsies after this rejection episode demonstrated grade 3 rejection of the VCA epidermis without extension to the dermis or fascia ( Figure 4B ).
Animal 22267 experienced several self-limiting acute rejection crises of the VCA following the taper of immunosuppression, starting on day 49. Histology demonstrated epidermal rejection. During later rejection episodes, epidermal rejection was seen on histology, with lymphocytic infiltrate also seen in the dermis and fascia. The final crisis resulted in loss of the VCA epidermis on day 95, and the underlying VCA dermis and fascia were subsequently rejected on day 110 ( Figure 4B ).
Mixed chimeras demonstrate donor-specific nonresponsiveness in vitro, despite rejection of VCAs
To assess the immune responses to donor antigens in MHC class II-mismatched chimeras, MLR assays were performed at various time points. Prior to conditioning, recipient animals demonstrated responses to donor and third-party antigens ( Figure 5A ). Following HSCT and VCA transplantation, these animals demonstrated nonresponsiveness to donor antigens on MLR ( Figure 5B ) that persisted long term following cessation of immunosuppression ( Figure 5C ). Responses to third-party antigens were preserved, demonstrating donor-specific nonresponsiveness.
To assess the immune responsiveness to donor antigens in MHC class I-mismatched chimeras, CML assays were performed. These animals demonstrated responsiveness to donor and third-party antigens prior to conditioning ( Figure 6A ). Following HSCT and VCA transplantation, MHC class I-mismatched chimeras demonstrated donorspecific nonresponsiveness on CML ( Figure 6B ) that persisted long term after tapering the immunosuppression ( Figure 6C ). Donor-specific nonresponsiveness in vitro persisted in MHC class I-mismatched chimeras even after rejection of VCA skin.
To assess the role of regulatory T cells (Tregs) in maintaining donor-specific nonresponsiveness, CD25 + cell-depleted MLR and CML assays were performed after day 150. CD25 + cell-depleted PBMCs from MHC class IImismatched chimeric animals remained unresponsive to donor antigen by MLR assays ( Figure 7A) . Similarly, CD25 + cell-depleted PBMCs from MHC class I-mismatched chimeras remained unresponsive to donor antigen by CML assays ( Figure 7B ). Responses to third-party antigens were preserved across MHC class II and I barriers.
No alloantibody was detected in MHC class Imismatched chimeras following rejection of VCA skin Despite rejection of VCA skin, the presence of cytotoxic antidonor alloantibody was not detected in any MHC class I-mismatched chimeric animal ( Figure 8A ). Similarly, flow cytometric analysis did not reveal any detectable antidonor IgM or IgG antibodies following VCA skin rejection ( Figure 8B ). 
Recipient-type CD8
+ lymphocytes infiltrate the rejecting VCA skin of MHC class I-mismatched chimeric animals Enhanced CD3 + cell infiltrates were observed on immunohistochemistry of skin biopsies from VCAs of MHC class I-mismatched chimeras during rejection (Figure 9A ) compared with tolerant VCAs from MHC class II-mismatched chimeras ( Figure 9B ). To further characterize the local cell populations that may contribute to VCA tolerance or rejection, VCA biopsies were separated into epidermal and dermal components, and isolated leukocytes were analyzed by flow cytometry. These demonstrated higher levels of recipient-type CD8 + lymphocytes in the epidermis and dermis of rejecting VCA skin of MHC class I-mismatched chimeras ( Figures 9C-F) .
To characterize regulatory cells in VCAs, the presence of CD4 + CD25 + FoxP3 + cells was determined using immunohistochemistry and flow cytometry. Donor and recipient FoxP3 + cells were detected in the VCAs of all chimeric animals ( Figure S1 ).
Discussion
In this study, we used a mixed chimerism-based tolerance model in MGH miniature swine to determine the role of MHC matching between donors and recipients in VCA skin tolerance. We found that long-term tolerance of VCAs, including the skin, can be achieved in mixed chimeras when MHC class II antigens are fully mismatched between donors and recipients. In contrast, MHC class I-mismatched chimeras experienced rejection of VCA skin, characterized by the presence of recipienttype CD8 + lymphocytes. Consequently, in our miniature swine model, MHC matching was a key determinant of VCA skin tolerance.
Similar to MHC class II-mismatched chimeras and haploidentical chimeras in previous studies, MHC class I-mismatched chimeric animals demonstrate stable mixed chimerism in the peripheral blood, thymic chimerism, and bone marrow engraftment of donor cells, which are all associated with robust allograft tolerance. The VCA outcomes in MHC class I-mismatched chimeras-despite persistence of chimerism, no detection of systemic antibody formation, and maintenance of systemic donor-specific nonresponsiveness in vitro-indicate that skin tolerance may be mediated locally in this model. Rejection of VCA skin in MHC class I-mismatched chimeras was associated with lymphocytic infiltrate. It is unclear whether this is due to recruitment of these cells from the periphery or local proliferation of cells within the VCA itself. One scenario may be that the early lymphocyte infiltrate into the VCA contains alloreactive cells that persist locally within the VCA and avoid the systemic mechanisms of tolerance induction following HSCT. These cells may then mediate skin rejection once immunosuppression is tapered. Expeditious identification and targeting of alloreactive T cells may be an important strategy to achieve clinical VCA tolerance. Previous studies have demonstrated that administration of Tregs can suppress CD8
+ lymphocytes during the initial T cell priming by alloantigen but not during the effector stage, thereby decreasing cellular invasion into the skin and preventing tissue damage (25) . Such methods may facilitate induction of VCA transplant tolerance and may limit VCA skin rejection in the conventional immunosuppression setting.
Among the MHC class I-mismatched chimeras in this study, two of three animals rejected the VCA skin without rejection of the underlying fascia. In the third animal, VCA skin rejection was followed by rejection of the underlying fascia. The reason for the more thorough rejection in this animal is not clear. Future large animal experiments determining whether rejection of VCA skin predisposes to abrogation of tolerance of other VCA tissues may have important implications for the development of clinical tolerance protocols.
Our findings in skin are surprising in the context of previous MGH miniature swine studies of solid organ transplantation in which tolerance across an MHC class I disparity was easier to induce than across MHC class II barriers (26) (27) (28) . Several hypotheses can be suggested to explain these results.
The propensity of transplanted skin to reject is demonstrated by the high frequency of acute rejection episodes affecting the skin in clinical face and hand transplant recipients, performed under the cover of conventional immunosuppression. There has been a recent increase in the understanding of skin-resident immunology, demonstrating a variety of resident cells such as macrophages, dendritic cells, Langerhans cells, and memory T cells. The presence of billions of memory T cells within the skin is driven by local inflammation and cutaneous infections. This dense, tissue-resident immune system is able to mount specific localized responses in the skin without systemic help, including responses mediated by skinresident CD8 + lymphocytes. In a recent mouse experiment using stable mixed chimerism, skin rejection was targeted toward non-MHC alloantigens, whereas tolerance of the MHC was maintained (29) . It is possible that non-MHC skin-specific antigens may drive skin-localized rejection responses despite tolerance protocols or systemic high-dose immunosuppression. The presence of these alloantigens has been used to explain skin rejection despite tolerance of other organs (3, 29, 30) .
The results of the present study suggests that any skin-specific antigens are associated with MHC class I. Comparing the rejected VCA skin of MHC class Imismatched chimeras with the tolerant VCAs of MHC class II-mismatched chimeras or haploidentical chimeras raises the possibility that the sharing of MHC class I antigens between donor and recipient can control the rejection response to the problematic skin alloantigens. Linked suppression to transplantation antigens presented indirectly on self-MHC has been described and may facilitate acceptance of skin in the setting of MHC class I matching between donors and recipients (31).
The rejection of VCA skin in MHC class I-mismatched chimeras may also be explained by a small subset of CD8 + T cells with a surface phenotype typical of memory cells, which are found in the periphery but not the thymus, that express NK cell-like killer inhibitory receptors (32, 33) . Recent work has demonstrated that potent resident memory CD8 + T cells exist in the skin (34, 35) . It is, therefore, possible that infiltration of the skin by recipient-type memory CD8 + T cells expressing killer inhibitory receptors may result in the rejection episodes targeted toward the disparate MHC class I antigens following the weaning of immunosuppression. Such a response might be mitigated in the presence of self-MHC class I antigens in mixed chimeras across haploidentical barriers, which could explain why haploidentical mixed chimeras accept VCAs.
Our findings can also be explained by the alternative hypothesis that tolerizing to allogeneic MHC class II antigens in MHC class II-mismatched chimeras (as well as in haploidentical mixed chimeras) mediates skin tolerance through induction of local regulatory tolerance. Recent small animal work in which transient depletion of FoxP3 + cells in stable chimeras resulted in skin rejection indicate that Tregs may play an important role in maintaining tolerance of transplanted skin (29) . In other experiments, Langerhans cells in the skin have been shown to induce skin-resident Tregs, dependent on MHC class II antigen presentation (36) . In the current study, we demonstrated no evidence of systemic regulatory tolerance in either MHC class I or II-mismatched chimeras. However, consistent with studies of renal allograft rejection, high numbers of FoxP3 + cells were identified in rejecting VCA skin (37) . Although donor and recipient FoxP3 + cells were identified in both MHC class I-and II-mismatched chimeras, the contributions of these cell types to tolerance were not determined. Further work is required to determine the role of donor and recipient FoxP3 + cells within the VCA and whether the presence of mismatched allogeneic MHC class II antigens is able to mediate regulatory tolerance.
Lymphocytes infiltrating the skin of rejecting VCAs were identified from the analysis of skin punch biopsies. A limitation of this study is that we have not demonstrated the function of these infiltrating cells. Future work to isolate sufficient numbers of cells from rejecting skin and to determine their alloreactive potential will help establish whether therapeutically targeting skin-infiltrating CD8 + lymphocytes can permit induction of tolerance. It is also important to consider that we used the same lines of MGH miniature swine within each group. Given that the MGH miniature swine are an inbred herd, it is possible that fixed differences in minor histocompatibility antigens between SLA gg donors and SLA dd recipients, not shared by SLA gg donors and SLA cc recipients, may result in the differential VCA skin rejection between groups in this study. We consider this unlikely because the MGH miniature swine breeding program is designed to fix MHC haplotypes while allowing variability in minor antigens within lines (38) . Line-specific outcomes can be definitively excluded in future studies by repeating these experiments using alternative recombinant haplotype lines to test selective MHC class I differences.
In summary, we demonstrated that the specificity of MHC antigen matching is critical to VCA skin tolerance in an MGH miniature swine model. The results of this study may have implications for the selection of donors and recipients chosen for VCA tolerance protocols. In addition, future work to determine the underlying mechanisms resulting in the disparate skin outcomes seen across MHC class I and II barriers may identify therapeutic strategies for robust VCA tolerance across full MHC mismatches.
